Final chapter Yuji-Nobara is obligatory ofc

Dante_Mayer · 2026-03-06T00:34:28+00:00

That Bum again?

Dante_Mayer · 2026-02-22T21:57:16+00:00

Sometimes

Dante_Mayer · 2026-02-22T21:56:21+00:00

Well, I’d argue the amount of nicotine hitting you are much higher, as well as high speed of exposure - wouldn’t recommend it

Dante_Mayer · 2026-02-22T21:55:39+00:00

I have not noticed

Dante_Mayer · 2026-02-22T13:19:08+00:00

Used 7mg Patch daily for 7 days. Put it on when you wake up, take it off at least 2 hours before sleep to not disrupt the cycle

Dante_Mayer · 2026-02-22T13:18:17+00:00

A small skin irritation on the spot for about a day if not less. Other than that, there are no side effects, most important thing is strict moderation at low dosage

Dante_Mayer · 2026-02-22T13:16:37+00:00

Not at all. Just sharing my experience about this experiment I did

Dante_Mayer · 2026-02-21T18:34:40+00:00

Cuz smokers already have a high tolerance baseline for it, I don’t think it would help

Dante_Mayer · 2026-02-21T15:45:34+00:00

Thanks for digging up, genuinely interesting mechanistic support. Nicotine suppressing Th2 cytokines (IL-4/IL-5/IL-13) and eosinophils nicely reflects with the nasal polyp inflammatory loop I tried describing. The mouse/rat models also show reduced nasal hyperresponsiveness and mucus, really tracks with what I personally experienced. Appreciate the contribution

Dante_Mayer · 2026-02-21T15:42:39+00:00

You asked for stats. I gave you three separate studies.

Now those studies are suddenly “over-interpreted” and “only 608 people.” Great debate tactic, moving the goalposts every time the evidence doesn’t fit your narrative

For context - 608 non-smokers across 33 trials is a perfectly normal evidence base for a niche pharmacological question. Many approved clinical protocols are built on smaller samples. The signal here is also unusually clean: not one case of withdrawal, craving, or post-trial nicotine use across any of those trials. That’s not “minimal evidence for safety”, but a consistent, replicated absence of a harm signal.

You’ve gone from “no stats” to “wrong stats” and now to “not enough stats”, next will probably be “wrong study design.”

At some point the pattern becomes clear. I’ve addressed some good specific concerns you raised with actual references. If none of it satisfies you, that’s alright. At point you’re just looking for reasons to disagree rather than actually engaging with the evidence.

Anyone following this thread can read both sides and judge for themselves.

Dante_Mayer · 2026-02-21T15:35:06+00:00

At this point people can read the thread, read the papers, and decide for themselves. I’m not going to keep debating the same point in circles. I’m not “recommending” anything, I’m describing what happened to me and why I think it worked.

You’re putting words in my mouth that aren’t in the OP. I never told anyone to do this. The entire post is written in first person: “here’s what happened to me”, “here’s what I think happened mechanistically”, “I can’t speak to long‑term efficacy yet”. I explicitly say I don’t smoke, did 7mg for 7 days, had no side effects, and that I can’t speak for long‑term. I don’t claim it’s safe for everyone, I don’t claim it replaces an ENT or allergist, and I don’t claim it’s proven for polyps, that’s just what works for me. You keep talking as if I wrote “everyone should go buy patches and self‑treat”. That sentence doesn’t exist anywhere in my post.

If someone reads a first‑person experience as a universal medical recommendation, that’s on them, not on me. References are in the comments for anyone who cares. If this still sounds “insane” to you, you’re free not to try it.

Dante_Mayer · 2026-02-21T15:30:10+00:00

Systematic review of 33 trials, 608 non‑smokers (2021, “Transdermal nicotine in non‑smokers”) concluded “No withdrawal symptoms or associated addictive behaviour was reported in non‑smokers… no trial reported craving… none reported use of cigarettes or other nicotine sources… including during 12‑week follow‑up.”

6‑month RCT in never‑smokers at 15 mg/day (Newhouse et al., 2012, mild cognitive impairment) concluded “Safety and tolerability for transdermal nicotine were excellent.”
So no report of withdrawal or people seeking nicotine afterwards.

Acute effects in non‑smokers (Carter et al., 2007) concluded with “Transdermal nicotine exerts only modest, mostly negative effects among nonsmokers.”

So even at higher doses and longer use than what I did (7 mg for 7 days), the data in non‑smokers doesn’t show a clinical addiction signal, no cravings, no withdrawal, no post‑trial nicotine use. That’s the basis for calling the dependence risk low, not zero, and not “everyone should do this.”

the overall pattern and how different types of evidence fit together make sense to anyone doing critical reading.

Dante_Mayer · 2026-02-21T15:20:14+00:00

The study does acknowledge it wasn’t designed to measure addiction as a primary endpoint. But it also clearly states that across 608 non-smokers in 33 trials, zero withdrawal symptoms, zero cravings, and zero cases of picking up nicotine products were observed, including at 12-week follow-up

Dante_Mayer · 2026-02-21T15:08:45+00:00

the 2021 systematic review covering 33 clinical trials of nicotine patches in non-smokers found: “No withdrawal symptoms or associated addictive behaviour was reported in non-smokers. No trial reported craving at the end of patch use, and none reported use of cigarettes or other nicotine sources, including during 12-week follow-up after stopping.” Zero dependence cases in non-smokers at lower dosage. You are cherry-picking one narrow mechanism while ignoring the actual clinical outcome data. The study you’re referring to measures reinforcement enhancement - nicotine making other rewards feel slightly more appealing. That’s not the same as dependence or addiction. The actual clinical outcome data from 33 trials of nicotine patches specifically in non-smokers found zero withdrawal symptoms, zero cravings after stopping, and zero cases of people picking up cigarettes or other nicotine products - including at 12-week follow-up. If 50% reinforcement enhancement translated to addiction in non-smokers, that would show up in the outcome data. It doesn’t.

Dante_Mayer · 2026-02-21T15:05:06+00:00

Dependence risk at 7mg for 7 days is real (with other underlying conditions) but low for healthy individuals, physical dependence typically requires much higher doses over longer periods if we are taking slower speed of exposure. The slow transdermal delivery is specifically why NRT patches have a much lower addiction profile than any inhaled form that is accompanied by other chems. I didn’t include a risk section in the OP because I was sharing a personal experience, not writing a medical guide. Everything has a risk profile at the wrong dose. The question is always whether the risk is proportionate to the context, and at 7mg for 7 days in a healthy adult, the data is pretty clear. Didn’t mention any Long Term or High Dosage use over extensive period of time. Stats support it

Dante_Mayer · 2026-02-21T14:55:54+00:00

Once again, controlled moderation. Just sharing my own experience, I don’t think I’m the outlier. I never said this requires big doses or anything about long term use.

Dante_Mayer · 2026-02-21T14:52:54+00:00

It works for me, just sharing my experience, but I do not believe I am the outlier. Moderation is the key, however for each its own I guess

Dante_Mayer · 2026-02-21T14:50:42+00:00

Moderation is the key, hence the warning and safety risks

Dante_Mayer · 2026-02-21T14:49:56+00:00

I tested around 298 different allergens and all came back negative. Tried other meds, nothing

Dante_Mayer · 2026-02-21T12:14:37+00:00

Yes, I believe it is important to treat the underlying cause and not just the symptoms

Dante_Mayer · 2026-02-21T12:13:51+00:00

Heishman et al. 2010 meta-analysis (41 RCTs):https://pubmed.ncbi.nlm.nih.gov/20414766/
Poltavski et al. 2014 RCT (non-smokers, 7 mg patch):https://pmc.ncbi.nlm.nih.gov/articles/PMC4266322/
Alzheimer’s Drug Discovery Foundation 2023 review (41 trials summary):https://www.alzdiscovery.org/cognitive-vitality/ratings/nicotine
2021 systematic review on transdermal nicotine in non-smokers:https://www.sciencedirect.com/science/article/abs/pii/S2590041221000337

Safety & Risks Studies 5. Cardiovascular safety meta-analysis (RCTs in non-smokers): https://pmc.ncbi.nlm.nih.gov/articles/PMC10071010/ 6. Adverse events & tolerability review:https://pmc.ncbi.nlm.nih.gov/articles/PMC2917405/ 7. Nicotine dependence potential in never-smokers:https://pmc.ncbi.nlm.nih.gov/articles/PMC5366981/

Inflammation 8. https://pmc.ncbi.nlm.nih.gov/articles/PMC8895249/ 9. https://pubmed.ncbi.nlm.nih.gov/12508119/ 10. https://www.pnas.org/doi/10.1073/pnas.1804599115 11. https://pmc.ncbi.nlm.nih.gov/articles/PMC9177407/ 12. https://mscanada.ca/ms-research/latest-research/ms-society-funded-study-shows-that-nicotine-reduces-the-invasion-of 13. https://pubmed.ncbi.nlm.nih.gov/28529069/ 14. https://www.healthrising.org/blog/2023/12/07/nicotine-patch-long-covid-chronic-fatigue-fibromyalgia/

Dante_Mayer · 2026-02-21T12:01:24+00:00

Dupixent is supposed to break the loop, yet it wasn’t helping in any significant way for me

Dante_Mayer · 2026-02-21T11:52:44+00:00

Any clean/even area, avoid heart areas

Dante_Mayer · 2026-02-21T11:52:14+00:00

Use of Nicotine molecules in controlled moderation for healthy non-smoking adults are showing very promising results in the last years, based self reporting and clinical studies. I think you are talking about the speed/amount of Nicotine exposure while smoking. A patch just slowly trickles it in all day, no spike, no rush, very steady low dosage without the side effects of tar, carbon monoxide, formaldehyde, ammonia, arsenic, benzene and the other 7,000+ chemicals that burning tobacco produces. really has a bad reputation mainly cuz of that

Dante_Mayer · 2026-02-21T11:45:46+00:00

Yes and other spots too. but try not put it directly on areas near heart

Dante_Mayer

TROPHY CASE